Document:

exh_411.htm

Exhibit 4.11

THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Service Agreement - Y

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

THIS SERVICE AGREEMENT Y is made and entered into this ___________ day of October, 2014 (the “Service Agreement”).

	
BETWEEN:

	

[****], a corporation duly incorporated under the laws of Canada and having its principal place of business at [****];

	
  

	

(hereinafter referred to as “[****]”)

	
AND

	
RedHill Biopharma Ltd., a company duly incorporated under the laws of Israel, and having its principal place of business at 21 Ha’arba’a St., Tel-Aviv, 64739 Israel;

	
  

	
(hereinafter referred to as the “Client”)

	
  

	

([****] and the Client are at times referred to individually as the “Party” and collectively the “Parties”)

RECITALS

	
A.  

	

The Client and [****] entered into a Master Service Agreement dated on the 7th day of August, 2012 (the “MSA”).

	
B.  

	
The Parties hereto wish to describe the services to be performed in connection with the MSA, subject to the terms and conditions set forth herein and in the MSA.

	
C.  

	
Unless the context otherwise requires, all capitalized terms used in this Service Agreement shall have the meanings attributed to them in the MSA.

 

	
1.  

	
INTERPRETATION

 

The recitals of this Service Agreement as well as all of its Appendices form an integral part of this Service Agreement.

 

  

Page 1 of 13

  

CONFIDENTIAL

Service Agreement - Y

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
2.  

	
DESCRIPTION AND DELIVERABLES

 

The objective of this Agreement is to GMP manufacture, the warehousing, the analytical release testing and the stability storage and testing of the RHB-104 CTM resupply.

	
2.1-  

	
API, excipients and packaging components reception and storage

	
2.1 a)  

	
API sourcing

It is estimated that sufficient quantities of fully released GMP clarithromycin API and GMP clofazimine API are available at [****] and the Client at its own cost will ship to [****] sufficient quantities of GMP rifabutin API (collectively the clarithromycin API, the clofazimine API and the rifabutin API are called “APIs” and individually “API”). Upon reception of the GMP rifabutin API [****] will execute a full release testing of the material according to GMP requirements. Should additional APIs be required, the sourcing will be the exclusive responsibility of the Client. Upon request by the Client, [****] could characterize and analyze the APIs which will be considered Extra Work.

	
  

	
Cost:

	
[****]

	
* 

	

It is estimated that sufficient quantities of each of GMP clarithromycin API and GMP clofazimine API are available at [****] to execute the manufacture of the CTM. However the Client will source and ship to [****] sufficient quantities of GMP rifabutin API for the manufacture of the Drug product included in this Agreement.

The cost includes:

	
·

	

the reception of one lot of GMP rifabutin API (i.e., documentation review, material registration in [****] inventory, and material sampling following GMP requirements) (If API lot is in more than one container then the sampling and ID testing of each of the additional containers will be considered Extra Work at 200$/additional container),

	
·

	

the full testing for the release of one lot of GMP rifabutin API using validated method. (Client will ship the GMP rifabutin API to [****] with the complete certificate of analysis and related documentation to assure API conformity to the appropriate regulatory authorities),

	
·

	
the GMP warehousing of the Client’s Materials (e.g., API, raw material, objects, inactive ingredients) for the period where the Project is active and for a volume not exceeding 1 m3. If the material need to be stored for a longer period of time or the volume of the material is more than 1 m3 then the storage cost will be considered Extra Work or the material shipped at Client.

The cost does not include:

	
·

	
The purchase of the analytical reference materials to be used as a standard, if needed, reference impurities (synthesis by-products, Related Substances, metabolites) of known purity, HPLC columns, and any dedicated peripherals (e.g., guard column) and reagents.

	
·

	
The release testing of any additional material (i.e., additional API) should the Client change the drug product material specifications or API source or any decision taken by the Client that requires additional analytical testing.

	
·

	
The repackaging of material (if required) as well as the shipping cost and custom fees, if any.

	
·

	
The destruction fees of any material after being pre-authorized by the Client.

	
·

	
Documentation fees for the shipment or reception of GMP API or GMP drug products at 200$/ event (i.e., reception or reception).

	
·

	
Sampling fees of 200$/ containers.

	
·

	
The shipping document preparation and shipment of material.

  

Page 2 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
2.1 b)  

	
GMP Materials (excipients and packaging components) storage and handling-

[****] will handle the reception, the full release testing, the shipping and the storage of GMP Materials (i.e., excipients and packaging materials) in its cGMP warehouse.  All material handling operations and storage conditions will respect the ICH GMP requirements.

	
  

	
Cost:

	

[****]

	
* 

	
The cost includes:

	
·

	

The reception of 10 lots of excipients and packaging components (i.e., documentation review, material registration in [****] inventory, and material sampling following GMP requirements) as well as their full release testing as per the [****] (The cost is based on the hypothesis that all GMP material will be received in one single shipment at 200$/ shipment and the full release testing of 10 GMP materials at an average cost of [****] of GMP material received. Any additional shipment or reception of GMP material will be considered as Extra Work at [****] or reception. Any additional sampling and testing of GMP material received will be considered Extra Work at [****] of GMP material received.).

	
·

	

The GMP warehousing of the APIs and the drug product until completion of the study. If the material needs to be stored for a longer period of time then the storage cost will be [****]/ month.

	
·

	
All the GMP Materials, APIs and RHB-104 drug products must have a volume of less than 1 m3.

The cost does not include:

	
·

	
The cost of APIs.

	
·

	
The purchase cost of the reference materials to be used as a standards and reference impurities (synthesis by-products, degradation products, metabolites) of known purity, if required.

	
·

	
Additional packaging or repackaging of APIs, Drug Products or any GMP material will be considered Extra Work.

	
2.2-  

	
Manufacturing of the Clinical Trial Material (CTM)

The CTM manufacturing process, manufacturing, packaging, equipment calibration and validation, will be done by [****] GMP laboratory. All the manufacturing, packaging and analytical equipments that will be used for the CTM will be calibrated, validated and released for their cleanliness prior to their utilization.

	
2.2 a)  

	
Manufacturing and bulk packaging

[****] will manufacture and package the single dose strength of RHB-104 capsule as per the optimized formulation developed in the execution of Service Agreement N (document 004-140225rev4).

Specifically with respect to manufacturing, packaging and bulk labeling, the followings items will be provided by [****]:

	
a)   

	
Recommendation and justification of specific finished product release specifications,

	
b)   

	
Redaction of Master Manufacturing File (MMF)

 

  

Page 3 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
c)   

	
The CTM will be manufactured and packaged in labeled* double lined sealed LDPE bags inserted in hard shell sealed barrels:

	 	
·

	
RHB-104 capsule      –[****] units

	
Cost:

	
145,000$**

	
* 

	
The labelling on the bags and barrels will include the basic information for GMP drug products (i.e., Name of sponsor, date of manufacturing, Lot number and storage conditions). This Agreement does not include preparation of special packaging and labelling which would require randomization, patient kits preparation of special shipments of clinical supplies.

	
**

	

The cost is based on the assumption that one batch of [****] RHB-104 capsules will be manufactured and packaged within the same manufacturing campaign. The cost includes the GMP excipients, the GMP packaging materials, the manufacturing, the bulk packaging, the labelling, the cleaning verification of the manufacturing suites and the equipments for one manufacturing campaign. The cost does not include the transportation cost of the clinical supplies, the broker and custom fees, the cost of the APIs. No manufacturing engineering batch of the drug product will have been executed using the new RHB-104 capsule formulation developed by [****] in the execution of Service Agreement N prior to the execution of this GMP manufacturing campaign and thus, [****] could not be held responsible for batch failure unless the failure is du to a [****] negligence or wilful misconduct. Furthermore, the manufacturing campaign will last 10 working days. The manufacturing campaign will start when the APIs are brought in the GMP manufacturing suites and will be terminated when the GMP manufacturing suites will have been released for their cleanliness. Should the manufacturing campaign be delayed by the Client, the Client’s suppliers, the Client’s APIs or any other factors outside the control of [****], every additional day to the GMP manufacturing campaign will be considered Extra Work at [****]/ day for GMP suite rental and labour cost may also apply in addition to the suite rental.

2.2 b) Packaging and labeling of the Clinical Trial Material (CTM) (optional)

Specifically with respect to packaging and labeling, the followings items will be provided by [****]:

	
a)  

	
Redaction of Master Manufacturing File (MMF); and

	
b)  

	

The RHB-104 capsules of the [****] units batch will be packaged in induction sealed HDPE bottle containing [****]; and

	
c)  

	

Labeling of bottles in a ratio of two RHB-104 bottles to one RHB-104 placebo bottle (i.e., [****]) using the labels to be provided by the Client.

The followings items will be provided by the Client to [****]:

	
a)  

	

About [****]; and

	
b)  

	
The randomization list; and

	
c)  

	
The labels.

  

Page 4 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

 

	
Cost:

	

[****]

	
* 

	
This cost is not included in the total cost of the study in section 7 and should Services included in this section required by the Client it will be considered Extra Work and invoiced monthly. The cost is based on the assumption that [****] RHB-104 capsules will be bottled [****] will be labelled with labels to be provided by the Client AND all the bottling and the labelling will be executed within the same manufacturing campaign. The cost includes the GMP packaging materials, the packaging, the labelling, the cleaning verification of the packaging suites and the equipments. The cost does not include the transportation cost of the clinical supplies, the broker and custom fees, the preparation of Patient Kits. If the Services included in this Agreement is executed within the same manufacturing campaign as of the manufacturing of the RHB-104 capsule (Section 2.2 a)) and the bulk packaging is not required then [****]$ will be subtracted from the discounted cost above.

2.2 c) Release testing of CTM and cleaning verification

The validation of the analytical methods for the release testing of the CTM and for the cleaning verification has already been validated. All analysis will be performed using the validated methods. Except for the cleaning verification all of the analyses are outsourced to a [****] qualified third Party laboratory.

Analyses to be performed on CTM are:

	
·

	
appearance,

	
·

	
Identification,

	
·

	
water content (KF),

	
·

	
assay* and degradation products*,

	
·

	
microbiology,

	
·

	
content uniformity,

	
·

	
dissolution** and disintegration time.

	
Cost:

	
10,965$***

	
* 

	
Assay and Related Substances for the three APIs for RHB-104.

	
**

	

[****].

	
***

	

The cost is not discounted as all of the CTM analyses are outsourced to a Third Party qualified laboratory. The cost includes the analysis of [****] (i.e., RHB-104 capsules), the analysis of [****] for cleaning verification for one GMP manufacturing campaign. Except for the cleaning verification all the analytical methods for release testing have been validated by a third Party [****] qualified laboratory.

2.2 d) Stability study of CTM and cleaning verification

The validation of the analytical methods for the analysis of the CTM has already been validated by a qualified third Party laboratory. All analysis will be performed using the validated methods.

  

Page 5 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

The CTM will be stored in cGMP stability chambers at [****], and the samples analyzed using the Client’s validated methods. The single strength RHB-104 capsule will be characterized for appearance, assay, related substances, dissolution*, disintegration and water content using the schedule below.

The following stability testing schedule will be used and modified per mutual agreement:

	
Storage Condition

	
Time point (Month)

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	
-

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	
-

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	

[****]

	
-

	

[****]

	

[****]

	

[****]

	
-

	
-

	
-

	
-

	
-

	
-

X: Sample to be analyzed.

Y: Sample removed from chamber and analyzed only at the request of Client.

	
  

	
Cost:

	
74,120$**

	
* 

	

A dissolution test is [****].

	
**

	

The cost is not discounted as all of the CTM analyses are outsourced to a Third Party qualified laboratory. The cost is based on the analysis of [****].

	
2.3-  

	
Reports and submission documentation

	
·

	

Telephone meetings, [****] facility and quality audit by Client’s or Client’s representative will be held on an as needed basis.

	
·

	

Client or Client’s representative meeting in [****] facility will be held at Client’s request.

	
·

	
Progress reports will be provided on a Monthly basis or as needed.

	
·

	
Item reports will be provided as they are completed.

	
·

	
A final manufacturing report will be provided at the end of the study. It will include all the necessary regulatory submission documents related to manufacturing and packaging which include (but not limited to):

	
o  

	
The finished products release & stability certificate of analysis.

	
o  

	
In process testing results.

	
o  

	
QA Reviewed and audited Manufacturing and Packaging/labeling Documents.

	
o  

	
Certificate of cGMP compliance.

	
o  

	
Certificate of analysis of raw materials and packaging components.

	
o  

	
Any atypical report or Out-of-Specification reports.

Cost:                                        0$*

	
* 

	
Included in the costs of the previous sections.

 

  

Page 6 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
3.  

	
GENERAL PROJECT TIMELINES

 

 

  

Page 7 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
4.  

	
STARTING DATE AND COMPLETION

 

	
4.1  

	

Notwithstanding the date of signature of this Service Agreement, [****] shall start the performance of the Services within ten (10) business days after [****] satisfaction of the following:

	
4.1.1  

	
signature by the Client of this Service Agreement; and

	
4.1.2  

	
complete delivery by the Client of all of the items mentioned at sub-section 6.1 of section 6 hereof entitled “REQUIREMENTS”.

	
4.2  

	

This Service Agreement shall be deemed completed upon full delivery of the Services by [****] and receipt by [****] of the final and last payment for the Services.

 

	
5.  

	
ASSUMPTIONS

 

	
5.1  

	
The RHB-104 optimized formulation containing 95 mg Clarithromycin, 45 mg Rifabutin, and 10 mg Clofazimine will be manufactured for clinical supplies.

	
5.2  

	

Any subcontractor that will used within this project will need to satisfy the [****] quality audit. Otherwise Extra Work may be required to support subcontractors and/or take actions not to delay the project (e.g., [****] to purchase and release material after approval by the Client). Use of subcontractors must be approved in advance by the Client.

	
5.3  

	

[****] is not responsible for the qualification of any API manufacturer, any delays in the manufacturing of the APIs, the delivery of the APIs, and for the quality of the APIs purchased by the Client.

	
5.4  

	
If different lots of APIs are utilized in the execution of the Project and the physical and chemical properties of the different lots are different or, if the physical and chemical properties of the API intended to be utilized in the execution of this Projects differs from the expected API properties when this Agreement was signed by both Parties, then additional formulation development and/or manufacturing process adjustments and/or additional manufacturing time and/or additional sample analysis may be needed and if needed, they will be considered Extra Work and the Project’s time lines adjusted accordingly.

	
5.5  

	

When a decision is required to move the project forward, the Client will provide its decision in writing to [****] within a period of 5 days, or the project may be delayed. [****] will develop a final timeline for this project and all deviations will be immediately reported to the Client. [****] will make its best efforts to correct all deviations in order to maintain the project timeline.

  

Page 8 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
5.6  

	

Any analytical reference materials (e.g., standards and impurities) and dedicated materials (e.g., HPLC columns, speciality reagents) purchased by [****] and utilized solely for the execution of the Client’s Project and any other equipments or materials that are damaged by the Client’s API or APIs (e.g., corrosion, unusual ware, staining, contamination, loss of operational functions) or becomes dedicated to the Client’s Project or requires unusual cleaning efforts and resources due to the nature of the Client’s APIs will be considered Extra Work and invoiced at cost to the Client.

	
5.7  

	
The Client decided not to execute a stability study of the CTM.

	
5.8  

	

All shipments from [****] to the Client or to a designated location specified by the Client will be invoiced at cost as per the EXW ([****]) Incoterms® 2010. All shipments from Clients or from a designated supplier of the Client to [****] will be invoiced at cost as per the DDP (200 Armand-Frappier boulevard, Laval, Quebec, Canada, H7V 4A6) Incoterms® 2010.

	
5.9  

	
The Client is responsible to verify that the Services and deliverables provided in the execution of this Service Agreement do not violate or infringe any patent, trade secret or other proprietary or intellectual property right of any third Party.

	
5.10  

	

During an audit, [****] will allow the Client's representatives to examine the batch records, technical reports, methods and protocols pertaining to the Services. The assistance provided by [****] to the Client during an audit will, under no circumstances, give rise to the payment of additional expenses unless the audit last more than three working days (a working day consist of an 8 hour shift). Should additional time is required for the audit it will be considered Extra Work.

	
5.11  

	

[****] will allow the Client’s representatives to assist to the execution of the Services for a maximum period of one day per manufacturing campaign. Should the Client’s representative need additional time and/or if the normal execution of the Services is disturbed by the presence of the Client’s representative then [****] may consider it Extra Work.

	
5.12  

	
If different lots of APIs are utilized in the execution of the Project and the physical and chemical properties of the different lots are different or, if the physical and chemical properties of the API intended to be utilized in the execution of this Project differs from the expected API properties when this Agreement was signed by both Parties, then additional formulation development and/or manufacturing process adjustments may be needed and if needed, they will be considered Extra Work and the Project’s time lines adjusted accordingly.

  

Page 9 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

 

	
5.13  

	

The costs included in this Agreement for GMP manufacturing are based on the premises that all of the GMP manufacturing operations will be executed within the same manufacturing campaign, unless explicitly specified in section 2. Should the GMP manufacturing campaign be delayed or split in several manufacturing campaigns and where the delays or the split is not caused by [****] or by [****] qualified suppliers, the additional cost that may apply will be considered Extra Work.

	
5.14  

	

All of the Client’s Materials (e.g., API, raw material, objects, inactive ingredients) stored in [****] warehouse will not exceed a volume of 1 m3. Exceeding storage volume will be considered Extra Work

 

	
6.  

	
REQUIREMENTS

 

The Client shall provide to [****], at no cost to [****], the following:

	
6.1  

	

If the Client send additional APIs to [****] for the manufacture of the RHB-104, the GMP APIs, reference materials to be used as a standard, reference impurities (synthesis by-products, degradation products, metabolites) of known purity, the certificate of analysis, the BSE & TSE statements, the APIs manufacturer GMP certification.

 

	
7.  

	
COST AND PAYMENTS

 

	
7.1  

	

The cost of the Services is 247,701.00 $USD [****]. Any amount exceeding a total of 247,701$ requires a pre-approval in writing by the Client.

	
7.2  

	

The Client shall pay to [****] the following installments in US currency ($USD):

	
7.2.1  

	

[****] upon signature of this Agreement; and

	
7.2.2  

	

[****] at the completion of the CTM manufacturing; and

	
7.2.3  

	

[****] at the acceptance of the final CTM manufacturing report;  and

	
7.2.4  

	
Stability study of CTM invoiced monthly.

	
7.3  

	

Each of the above payments is subject to receipt of a non-disputed invoice from [****] and subject to the payment terms detailed in the Master Service Agreement.

  

Page 10 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

 

	
7.4  

	

Notwithstanding section 7.1, for any extra work not covered by this Service Agreement and agreed upon in writing between the Parties (the “Extra Work”), the Client shall pay to [****] the relevant sum as agreed in writing.  For any such Extra Work [****] will apply the hourly rates and other fees indicated in this Appendix I attached hereto for the performance of the Services (The costs of the Services for the Extra Work and described in section 7.1 are collectively, the “Fees”).

	
7.5  

	

Notwithstanding section 7.2 hereof, [****] will invoice the Client for the Extra Work, on a monthly basis for the Services that (i) have been pre-approved in writing by the Client, and; (ii) that have been delivered or rendered by [****].

 

	
8.  

	
CONFIDENTIALITY

 

	
8.1  

	
Confidentiality issues are covered per the Non Disclosure Agreement and the MSA.

 

	
9.  

	
REPRESENTATIONS AND WARRANTIES

 

	
9.1  

	

[****] hereby represents and warrants to the Client that:

 

	
9.1.1  

	
it is a duly organized and validly existing corporation under the laws of the jurisdiction in which it is incorporated;

	
9.1.2  

	
it has the necessary corporate power, authority, skills, and capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated hereby have been duly authorized.

	
9.2  

	

The Client hereby represents and warrants to [****] that:

 

	
9.2.1  

	
it is a duly organized and validly existing corporation under the laws of the jurisdiction in which it is incorporated;

	
9.2.2  

	
it has the necessary corporate power, authority, skills, and capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated hereby have been duly authorized;

 

	
10.  

	
TERMS AND CONDITIONS

 

	
10.1  

	

This Service Agreement shall be governed, construed and interpreted according to the laws in force in the [****] and the applicable laws of Canada therein, and the courts of the legal district of [****] (Canada) shall have exclusive jurisdiction to hear any and all disputes arising hereunder.

  

Page 11 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

 

	
10.2  

	
This Service Agreement is subject to the terms and conditions provided in the MSA and bind the parties as well as their respective successors, permitted assigns and legal representatives.

	
10.3  

	
This Service Agreement may be executed in counterparts, each of which shall be deemed to be an original and which together shall constitute one and the same agreement. This Service Agreement may also be executed between the Parties by exchange of facsimile transmissions or electronic transmissions in legible form, including without limitation in a tagged image format file (TIFF) or portable document format (PDF).

	
10.4  

	
The Parties hereto have requested that this Service Agreement be drafted in the English language.  Les Parties ont exigé que ce contrat de services soit rédigé en anglais.

 

IN WITNESS THEREOF, the Parties have executed this Service Agreement as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind the Parties they represent.

	

[****]

	 	
RedHill Biopharma Ltd.

	Per: 	
/s/

	 	

Per:

	/s/ Dror Ben-Asher	 
	Name: 	
[****]

	 	
Name: Dror Ben-Asher

	Title: 	
President

	
Title: CEO

	 
	 	  	 	 	  	 
	 	  	 	Per: 	
/s/ Ori Shilo

	 
	 	  	 	
Name: Ori Shilo

	 
	 	  	 	
Title: VP Finance and Operation

 

  

Page 12 of 13

  

CONFIDENTIAL

Service Agreement - Y 

RedHill Biopharma Ltd. – [****]

Manufacture of resupply of Clinical Trial Material of

[****] RHB-104 capsules

Appendix I 

 

Professional Consultation Rates

	
Professional

(Chemist or Engineer)

	
Hourly Rate*, **

($USD)

	
Senior scientist

	
[****]

	
Scientist

	
[****]

	
Technician

	
[****]

	
R&D laboratory overhead

( Equipment and supplies)

	
[****]

Analytical Services

	
Analyses

 

	
Cost / Sample *

($USD)

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****] ****

	
[****]

	
[****] ****

	
[****]

	
[****] ****

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

	
[****]

 

	
*

	

Prices can be changed by [****] without any prior notice. Prices apply only for non GMP work and analysis. GMP prices will be supplied on demand.

	
**

	
All expenses will be charged at cost.

	
***

	
Will be invoiced in addition to the professional fees when laboratory work is required.

	
****

	

A set-up charge of [****] method will be invoiced in addition to the sample cost.

 

 

Page 13 of 13exh_414.htm

Exhibit 4.14

THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Amendment 3 to Clinical Services Agreement

Sponsor’s study drug RHB-104

This Amendment 3 (“Change Order”) to the Clinical Services Agreement signed 15 June 2011 (“Clinical Services Agreement”), is by and among:

(1) RedHill Biopharma Ltd., having its principle place of business at 21 Ha’arba’a St., Tel Aviv 64739, Israel (hereafter “SPONSOR”);

(2) 7810962 Canada Inc., a Canadian corporation, having its principal office at 245 Victoria Ave, Suite 100, Montreal, Quebec, H3Z 2M6, Canada (hereinafter "MANAGER");

Is hereby made effective as of September 05, 2014 (“Effective Date”) and the parties hereby agree as follows:

1.     Amendment 3 to Clinical Services Agreement.

This Change Order constitutes an amendment to the Clinical Services Agreement pursuant to section 3.0 therein.  As such, this Amendment is subject in all respects to the terms and provisions of the Clinical Services Agreement.

2.      Scope of Work

In addition to the Services to be provided in the above-referenced Clinical Services Agreement, Manager will cause inVentiv Health Clinical to perform additional Services for Sponsor’s study drug RHB-104, in accordance with the Summary of Changes attached hereto and incorporated herein as Exhibit A. [****]

 

3.      Compensation

[****]

  

1

  

Payment due to Manager for the Services provided under this Amendment shall be made pursuant to the Agreement and the revised unit Payment Schedule attached hereto and incorporated herein as Exhibit B.

4.     Project Period

The term of this Amendment shall commence on the date of its execution and shall continue until the Services as described in the Clinical Services Agreement are completed, unless this Amendment or corresponding Clinical Services Agreement are terminated early in accordance with the Clinical Services Agreement.

By their signatures below, the parties hereto agree to the terms of this Amendment and represent that they are authorized to enter into this Amendment on behalf of their respective companies.

ACCEPTED AND AGREED TO:

 

	

RedHill Biopharma Ltd.

	 	

For 7810962 Canada Inc.

	 
	 	 	 	 	 	 
	
/s/ Dror Ben-Asher

	 	/s/ Alain Guimond PhD	 
	
Name: Dror Ben-Asher

	 	
Name: Alain Guimond PhD

	 
	

Title: CEO

	 	 	
Title: Senior Director of R&D

	 
	 	 	 	 	 	 	 	 
	Date: 	01 Dec 2014	 	 	Date	01 Dec 2014	 	 
	 	 	 	 	 	 	 	 
	
RedHill Biopharma Ltd.

	 	 	 	 	 
	 	 	 	 	 	 	 
	
/s/ Ori Shilo

	 	 	 	 
	
Name: Ori Shilo

	 	 	 	 	 
	
Title: Deputy CEO Finance & Operations

	 	 	 
	 	 	 	 	 	 
	Date: 	01 Dec 2014	 	 	 	 

 

  

2

  

Exhibit A  Summary of Changes

Study Assumption Changes

 

Changes to the parameters and assumptions for the study are defined below. Unless otherwise noted, activities will be performed according to the original contract. EU trial is removed from the study agreement

 

Change Order 03 for 7810962 Canada Inc. /Red Hill Biopharma Ltd.

 

Overview of major level changes

	
Category

	
Contract

	
Additional sites & protocol amendments

	
Rationale for change

	
Study Start- Up period

	
[****] months + [****] month hold period

	
 [****] months + [****] month hold period

	
 

No change

	
Enrolment period

	
[****] months

	
 [****] months

	
No change

	
Stats Timeline

	
[****] weeks

	
[****] weeks

	
no change

	
# of countries

	
[****]

	
[****]

	
no change

	
# of sites

	
[****]

	
[****]

	
Per client

	
# of subjects

	
[****]

	
[****]

	
Per client

	
# of CRF pages/book

	
[****]

	
[****]

	
[****]

	
# of unique CRF pages

	
[****]

	
[****]

	
[****]

	
# of PSVs

	
[****]

	
[****]

	
[****]

	
# of SIVs

	
[****]

	
[****]

	
[****]

	
# of RMVs

	
[****]

	
[****]

	
[****]

	
# of COVs

	
[****]

	
[****]

	
[****]

	
# of internal meetings

	
[****]

	
[****]

	
 [****]

	
# of client telecons

	
[****]

	
[****]

	
 [****]

	
Client Meetings

	
[****]

	
[****]

	
[****]

	
Investigator Meeting

	
1 F2F

	
No Change

	  
	
# of vendors

	
[****]

	
[****]

	
[****]

	
# of edit checks

	
220

	
220

 

	
No change

	
# of imports

	
54

	
54

 

	
 No change

	
# of SAEs

	
[****]

	
[****]

	
No change.

	
# of SAE Narratives

	
[****]

	
[****]

	
No change.

	
IVRS

	
Not Included

	
Not Included

	  
	
eCRF Changes

	

[****]

	

[****]

	

 [****]

 

  

3

  

	
1.1  

	
Revised Costs

 

Costs for this study are presented below in two categories, pass-through costs and professional fees.

 

	
1.1.1  

	
Pass-Through Costs

 

Pass-through costs are in US dollars and include those expenses listed below. inVentiv Health Clinical will invoice Client for actual costs in these areas, it being understood that any pass-through costs in excess of the amounts set out below will require the Client’s prior written approval. inVentiv Health Clinical will use its best efforts to keep actual costs to reasonable levels through adherence to inVentiv Health Clinical’s travel policy and prudent negotiation with outside providers. Pass-through costs are presented in the table below:

 

	
Task

	
Current

(USD)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Site Visit Travel

	
[****]

	
[****]

	
[****]

	
[****]

	
Investigators' Meeting Organisation

	
[****]

	
[****]

	
[****]

	  
	
Kick-off Meeting Travel/Attendance

	
       [****]

	
       [****]

	
[****]

	  
	
Shipping/Photocopying

	
[****]

	
  [****]

	
[****]

	  
	
Translation

	
[****]

	
[****]

	
[****]

	  
	
Regulatory Fees

	
[****]

	
[****]

	
[****]

	
[****]

	
Ethics Committee Fees

	
[****]

	
[****]

	
[****]

	 
	
EDC Studies/3G Cards

	
[****]

	
       [****]

	
[****]

	  
	
DSMB member fees

	
[****]

	
[****]

	
 [****]

	
[****]

	
EDC Fees (Oracle)

	
[****]

	
[****]

	
 [****]

	
[****]

	
CRA Face to Face Meeting Travel expenses

	
[****]

	
[****]

	
[****]

	  
	
 Pass Through Costs

	

[****]

	

[****]

	  	  

 

  

4

  

	
1.1.2  

	
Investigator Grants Costs

 

	
Investigator

Grants

	
Current

(NA USD)

	
NA

(USD)

	
Assumption Changes influencing the change in the budget

	
Additional Comments

	
$ [****]

	
$ [****]

	
No Change

	
Estimate only. Will be paid based on actual costs as approved by the Client.

 

	
1.1.3  

	
Professional Fees

 

Based on the parameters and assumptions outlined in the original proposal, inVentiv Health Clinical fees are categorised by major activity in the table below and in USD:

 

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Pre-study Activities

	  	  	  	  
	
Case Report Form Preparation/Review

	
[****]

	
  [****]

	

[****]

	

[****]

	
Data Management Plan Preparation/Review

	
[****]

	
 [****]

 

	

[****]

	  
	
Informed Consent Preparation/Review

	
[****]

	
 [****]

	

[****]

	

[****]

 

 

 
[****]

 

  

5

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
IRB/Ethics Committee Interactions

	
[****]

	
  [****]

	
[****]

	

[****]

 

	
Investigators' Meetings

	

[****]

	
No change

 

	
 No Change

	  
	
Investigator Site Contract

	
[****]

	
  [****]

	
[****]

	

[****]

 

  

6

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Investigator Recruitment

	
[****]

	
  [****]

	
[****]

	

[****]

	
Project Plan Preparation/Review

	

[****]

	

[****]

	

[****]

	

[****]

	
Protocol Preparation/Review

	

[****]

	

[****]

 

	

[****]

	
[****]

	
Randomization Schedule Preparation

	

[****]

	

[****]

	

[****]

	  
	
Study-Specific Form Preparation

	

[****]

	

[****]

	

[****]

	  
	
Training - Project-Specific

	
[****]

	
  [****]

	
[****]

	

[****]

	
Translations

	

[****]

	

[****]

	
 No change

	  
	
PROMIS

	
[****]

	
[****]

	
[****]

	

[****]

	
Monitoring/Site Management

	  	  	  	  

 

  

7

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Data Clean-up

	

[****]

	

[****]

	

[****]

	
 

	
Investigator Grant Administration

	

[****]

	

[****]

	

[****]

	

  

[****]

	
Laboratory Report Review

	

[****]

	

[****]

	

[****]

	
 

	
Serious/Significant Adverse Event Management

	
[****]

	
  [****]

	
[****]

	

[****]

	
Site Management

	
[****]

	
[****]

	
[****]

	

[****]

	
Remote Monitoring of Site Data

	
[****]

	
[****]

	
[****]

	

[****]

	
Site Visits - Pre-study Visits

	
[****]

	
 [****]

	
[****]

	

[****]

	
Site Visits - Initiation Visits

	
[****]

	
[****]

	
[****]

	

[****]

	
Site Visits - Routine Visits conducted on site

	

[****]

	

[****]

	

[****]

	

[****]

	
Site Visits - Close-out Visits at each site at Study End

	
[****]

	
 [****]

	
[****]

	

[****]

 

  

8

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Study Master File/Project File Set-up and Maintenance

	
 [****]

	
[****]

	
[****]

	

[****]

	
Patient/Site Recruitment

	

[****]

	

[****]

	
No change

	  
	
Client/CRO meeting

	
[****]

	
[****]

	
[****]

	

[****]

	
Regulatory

	  	  	  	  
	
Regulatory Documentation Preparation/Review

	
[****]

	
[****]

	
[****]

	

[****]

	
Project Management /Project Tracking

	  	  	  	  
	
Financial Project Management

	

[****]

	

[****]

	
 No change

	  

 

  

9

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Project Management

	
[****]

	
  [****]

	
[****]

	
[****]

	
Project Tracking / Communications

	
[****]

	
  [****]

	
[****]

	
[****]

	
Vendor Management

	
[****]

 

	
  [****]

	
[****]

	
[****]

	
Data Management

	  	  	  	  
	
Database Archiving

	

[****]

	

[****]

	

[****]

	  
	
Data Cleanup (DM)

	

[****]

	

[****]

	

[****]

	  
	
Data Management: Database Quality Control Inspection

	

[****]

	

[****]

	

[****]

	  
	
Database Design

	
[****]

	
  [****]

	
[****]

	

[****]

	
Dictionary Coding

	

[****]

	

[****]

	

[****]

	  
	
Edit Check Programming

	
[****]

	
[****]

	
[****]

	
[****]

	
Electronic Data Import

	
[****]

	
   [****]

	
[****]

	

[****]

	
Case Report Form Data/Document Transfers

	
[****]

	
[****]

	
[****]

	
[****]

	
EDC Fees

	

[****]

	

[****]

	

[****]

	  
	
Statistical Analysis and Table Generation

	  	  	  	  
	
Electronic Data Transfer

	

[****]

	

[****]

	
No Change

	  
	
Interim Analysis/Report Preparation and Review

	

[****]

	

[****]

	
No Change

	  
	
Statistical Analysis Plan Preparation/Review

	

[****]

	

[****]

	
No Change

	  
	
Table Generation

	

[****]

	

[****]

	
No Change

	  
	
Table/Listings Review

	

[****]

	

[****]

	
No Change

	  
	
Clinical Study Report

	  	  	  	  
	
Clinical Study Report Preparation/Review

	

[****]

	

[****]

	
 No Change

	  
	
Team Meetings

	  	  	  	  

 

  

10

  

	
Task

	
Current

(US Dollars)

	
Additional sites

& protocol

amendments

	
Assumption Changes influencing the change in the budget

	
Additional comments

	
Project Team Meetings - Internal Meetings

	
[****]

	
  [****]

	
[****].

	

[****]

	
Project Team Meetings - Client Teleconferences

	
[****]

	
[****]

	
[****]

	
 
[****]

	
Project Team Meetings - Kick-off Meeting

	

[****]

	

[****]

	

[****]

	  
	
Total Direct Costs

	

[****]

	

[****]

	  	  

 

Total Costs

 

	
Category

	
Total Costs($)

	
Current Contract

(USD)

	
Change in Scope #3

(USD)

	
Revised Total

(USD)

	
Pass-Through Costs

	

[****]

	

[****]

	

[****]

	
Investigator Grants Costs

	

[****]

	  	

[****]

	
Professional Fees

	

[****]

	

[****]

	

[****]

	
Discount

	

[****]

	

[****]

	

[****]

	
Revised Professional Fees

	

[****]

	

[****]

	

[****]

	
Grand Total

	

[****]

	

[****]

	

[****]

 

  

11

  

Exhibit B Payment Schedule

1.           PAYMENT TERMS

A.           Service Fees:

 

 

 

 

[****]

 

 

 

 

  

12

  

2.           Pass Through Costs:

 

	
(a)  

	
CO#2:  [****] of the average estimated expenses as set forth in the Expenses Estimate (exclusive of funds for investigator grants), totaling [****], will be due and payable upon execution of this Agreement. Prepayment for Out of Pocket Expenses (to be drawn down once paid and replenished once 75% depleted).  This process to continue until the end of the study.

 

	
(b)  

	
CO#3:  [****] of the average estimated expenses as set forth in the Expenses Estimate (exclusive of funds for investigator grants), totaling [****], will be due and payable upon execution of this Agreement. Prepayment for Out of Pocket Expenses (to be drawn down once paid and replenished once 75% depleted).  This process to continue until the end of the study.

 

	
(c)  

	
Actual pass-through expenses, as provided in the expenses estimate, will be billed as incurred by inVentiv Health Clinical

 

	
(d)  

	
Any unused funds will be returned within ninety (90) days from the date of the final reconciliation

 

3.           Investigator Grants:

 

	
(a)  

	
[****] 

 

	
(b)  

	
inVentiv Health Clinical will submit invoices for the amounts paid to investigators during the previous month.  Any amount exceeding the estimate investigator grant payments will be pre-approved by the Company.

 

	
(c)  

	
inVentiv Health Clinical will not make payments to investigators without having sufficient funds available in advance.

 

	
(d)  

	
Any unused funds will be returned within ninety (90) days from the date of the final reconciliation

 

4.           Payment Conditions:

	
(a)  

	
For all Services, pass through expenses and investigator grants invoiced, payments are due net thirty (30) days from invoice date as set forth in Terms, Item 2 of the Agreement.  In the event of a dispute, all undisputed portions of the invoice(s) are due within the above stated terms

 

	
(b)  

	
Payments shall be made in the currency identified above and shall be made free of any applicable local withholding taxes, charges or remittance fees.  Invoices will be inclusive of applicable taxes as determined by local laws and regulations

 

	
(c)  

	
inVentiv Health Clinical reserves the right to charge interest against any unpaid overdue balance at the rate of one and [****]

 

	
(d) 

	
All services and pass-through payments should be sent via wire or ACH

 

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]